https://www.cancernetwork.com/view/alpha-dart-overcomes-anatomical-constraints-in-inoperable-pancreatic-cancer2026-05-20T19:00:00Z2026-05-20T19:00:00Z https://www.cancernetwork.com/view/the-potential-benefits-of-once-daily-extended-release-ruxolitinib-tablets2026-05-20T18:00:00Z2026-05-20T18:00:00Z https://www.cancernetwork.com/view/fda-accepts-supplemental-bla-for-nogapendekin-alfa-combo-in-nmibc-subtype2026-05-20T15:00:00Z2026-05-20T15:00:00Z https://www.cancernetwork.com/view/novel-flt3-cd3-t-cell-engager-earns-orphan-drug-designation-in-r-r-aml2026-05-20T14:30:00Z2026-05-20T14:30:00Z https://www.cancernetwork.com/view/tip103-randomized-phase-3-clinical-trial-evaluating-atirmociclib-plus-letrozole-versus-a-cdk4-6-inhibitor-plus-letrozole-as-first-line-treatment-for-patients-with-hr-her2-advanced-metastatic-breast-cancer2026-05-19T23:00:00Z2026-05-19T23:00:00Z https://www.cancernetwork.com/view/104-katsis-1-randomized-phase-3-trial-evaluating-kat6-inhibitor-pf-07248144-prifetrastat-plus-fulvestrant-in-hr-her2-advanced-metastatic-breast-cancer-after-progression-on-cdk4-6-inhibitor-based-therapy2026-05-19T22:30:00Z2026-05-19T22:30:00Z https://www.cancernetwork.com/view/discussing-multidisciplinary-coordination-for-mitomycin-gel-delivery2026-05-19T22:00:00Z2026-05-19T22:00:00Z https://www.cancernetwork.com/view/artificial-intelligence-in-the-heart-of-nursing-practice2026-05-19T21:00:00Z2026-05-19T21:00:00Z https://www.cancernetwork.com/view/mechanistic-and-translational-insights-of-carv3-team-e-in-glioblastoma2026-05-19T19:00:00Z2026-05-19T19:00:00Z https://www.cancernetwork.com/view/nogapendekin-alfa-plus-bcg-exhibits-efficacy-advantage-in-nmibc-in-situ2026-05-19T16:00:00Z2026-05-19T16:00:00Z https://www.cancernetwork.com/view/fianlimab-combo-does-not-significantly-improve-pfs-in-advanced-melanoma2026-05-19T15:00:00Z2026-05-19T15:00:00Z https://www.cancernetwork.com/view/subcutaneous-isatuximab-may-optimize-multiple-myeloma-treatment-protocols2026-05-19T14:00:00Z2026-05-19T14:00:00Z https://www.cancernetwork.com/view/investigational-radioenhancer-shows-feasibility-in-stage-iii-nsclc2026-05-19T13:00:00Z2026-05-19T13:00:00Z https://www.cancernetwork.com/view/sc-q4w-in-practice-workflow-dose-modifications-and-patient-conversations2026-05-12T12:05:00.000Z2026-05-19T12:05:00Z https://www.cancernetwork.com/view/from-paloma-3-to-paloma-2-cohort-5-sc-q4w-dosing-evidence2026-05-12T12:05:00.000Z2026-05-19T12:00:00Z https://www.cancernetwork.com/view/105-real-world-overall-survival-with-palbociclib-plus-an-aromatase-inhibitor-ai-in-overweight-obese-patients-with-hr-her2-metastatic-breast-cancer-mbc-2026-05-18T22:30:00Z2026-05-18T22:30:00Z https://www.cancernetwork.com/view/106-treatment-durations-subsequent-treatments-and-switching-of-first-line-cyclin-dependent-kinase-4-6-inhibitors-in-patients-with-hr-her2-metastatic-breast-cancer-in-us-routine-clinical-practice2026-05-18T22:00:00Z2026-05-18T22:00:00Z https://www.cancernetwork.com/view/sac-tmt-significantly-improves-pfs-os-in-pretreated-endometrial-cancer2026-05-18T19:31:00.216Z2026-05-18T19:31:00.216Z https://www.cancernetwork.com/view/toxicity-from-cd19-bcma-therapy-may-inform-b-cell-malignancy-surveillance2026-05-18T18:01:43.101Z2026-05-18T18:01:43.101Z https://www.cancernetwork.com/view/frontline-sevabertinib-earns-fda-priority-review-in-her2-mutated-nsclc2026-05-18T17:37:52.036Z2026-05-18T17:37:52.036Z https://www.cancernetwork.com/view/fda-approves-t-dxd-in-2-indications-for-her2-early-breast-cancer2026-05-18T13:05:22.589Z2026-05-18T13:05:22.589Z https://www.cancernetwork.com/view/reflections-on-clinical-impact-and-future-data-needs2026-05-18T12:05:00Z2026-05-18T12:05:00Z https://www.cancernetwork.com/view/are-zedoresertib-and-lunresertib-an-efficacious-combo-across-solid-tumors-2026-05-18T12:00:00Z2026-05-18T12:00:00Z https://www.cancernetwork.com/view/summary-and-conclusions-of-litespark-0112026-05-18T12:00:00Z2026-05-18T12:00:00Z https://www.cancernetwork.com/view/107-updated-results-and-an-exploratory-analysis-of-esr1-mutations-esr1m-circulating-tumor-dna-ctdna-dynamics-from-serena-6-a-phase-iii-trial-of-camizestrant-cdk4-6-inhibitor-cdk4-6i-for-emergent-esr1m-during-first-line-1l-endocrine-based-therapy-and-ahead-of-disease-progression-in-patients-with-hr-her2-advanced-breast-cancer-abc-2026-05-17T22:30:00Z2026-05-17T22:30:00Z https://www.cancernetwork.com/view/108-long-term-safety-and-efficacy-of-first-line-next-generation-cdk4-selective-inhibitor-atirmociclib-letrozole-for-the-treatment-of-patients-with-hr-her2-metastatic-breast-cancer2026-05-17T22:00:00Z2026-05-17T22:00:00Z https://www.cancernetwork.com/view/investigators-initiate-dosing-in-phase-1b-2-trial-of-snb-101-in-es-sclc2026-05-17T16:00:00Z2026-05-17T16:00:00Z https://www.cancernetwork.com/view/109-extended-adjuvant-neratinib-in-her2-hr-early-breast-cancer-in-clinical-routine-final-results-from-the-multi-national-prospective-observational-study-eleanor2026-05-16T22:30:00Z2026-05-16T22:30:00Z https://www.cancernetwork.com/view/110-randomized-phase-ii-trial-evaluating-three-anti-diarrheal-prophylaxis-strategies-in-patients-pts-with-her2-hr-early-breast-cancer-ebc-treated-with-extended-adjuvant-neratinib-dianer-geicam-2018-06-2026-05-16T22:00:00Z2026-05-16T22:00:00Z https://www.cancernetwork.com/view/yoga-could-alter-cancer-related-fatigue-levels-across-solid-tumors2026-05-16T21:00:00Z2026-05-16T21:00:00Z https://www.cancernetwork.com/view/overcoming-knowledge-barriers-to-accessing-oncology-yoga-programs2026-05-16T19:00:00Z2026-05-16T19:00:00Z https://www.cancernetwork.com/view/mitomycin-administration-via-nephrostomy-tube-enhances-nursing-competency2026-05-16T17:00:00Z2026-05-16T17:00:00Z https://www.cancernetwork.com/view/sound-tools-may-reduce-anxiety-in-gynecologic-oncology-settings2026-05-16T16:00:00Z2026-05-16T16:00:00Z https://www.cancernetwork.com/view/identifying-psychoneurological-symptom-clusters-in-heme-malignancies2026-05-16T15:00:00Z2026-05-16T15:00:00Z https://www.cancernetwork.com/view/111-the-aurora-kinase-a-inhibitor-alisertib-alone-or-in-combination-with-endocrine-therapy-for-patients-with-estrogen-receptor-positive-human-epidermal-growth-factor-receptor-2-negative-er-her2-metastatic-breast-cancer-mbc-2026-05-15T22:30:00Z2026-05-15T22:30:00Z https://www.cancernetwork.com/view/112-first-line-1l-datopotamab-deruxtecan-dato-dxd-vs-chemotherapy-in-patients-with-locally-recurrent-inoperable-or-metastatic-triple-negative-breast-cancer-mtnbc-for-whom-immunotherapy-was-not-an-option-primary-results-from-the-randomized-phase-3-tropion-breast02-trial2026-05-15T22:00:00Z2026-05-15T22:00:00Z https://www.cancernetwork.com/view/moving-beyond-r-chop-the-future-of-upfront-precision-oncology-in-lymphoma2026-05-15T20:00:00Z2026-05-15T20:00:00Z https://www.cancernetwork.com/view/shifting-hematologic-and-solid-tumor-units-to-progressive-care-models2026-05-15T19:30:35.807Z2026-05-15T19:30:35.807Z https://www.cancernetwork.com/view/fda-approves-atezolizumab-in-mibc-post-cystectomy-with-ctdna-mrd2026-05-15T17:01:13.294Z2026-05-15T17:01:13.294Z https://www.cancernetwork.com/view/boosting-nurse-competency-with-antineoplastic-onboarding-in-oncology2026-05-15T16:05:47.374Z2026-05-15T16:05:47.374Z https://www.cancernetwork.com/view/perioperative-durvalumab-enfortumab-vedotin-improves-survival-mibc2026-05-15T15:00:19.884Z2026-05-15T15:00:19.884Z https://www.cancernetwork.com/view/chemo-induced-peripheral-neuropathy-may-persist-years-after-lymphoma-care2026-05-15T14:33:37.310Z2026-05-15T14:33:37.310Z https://www.cancernetwork.com/view/navigating-the-evolving-landscape-of-second-line-endometrial-cancer-care2026-05-15T14:00:00Z2026-05-15T14:00:00Z https://www.cancernetwork.com/view/moving-bispecifics-and-prophylaxis-to-outpatient-multiple-myeloma-care2026-05-15T12:00:00Z2026-05-15T12:00:00Z https://www.cancernetwork.com/view/how-does-the-removal-of-heparin-impact-safety-in-oncology-care-2026-05-14T23:00:00Z2026-05-14T23:00:00Z https://www.cancernetwork.com/view/tip113-herthena-pantumor01-nct06172478-expansion-of-a-global-phase-2-trial-of-her3-dxd-in-patients-with-advanced-metastatic-hr-her2-breast-cancer2026-05-14T22:30:00Z2026-05-14T22:30:00Z https://www.cancernetwork.com/view/114-comparing-an-ai-based-prognostic-test-with-a-21-gene-assay-for-recurrence-prediction-in-premenopausal-node-positive-hr-her2-breast-cancer2026-05-14T22:00:00Z2026-05-14T22:00:00Z https://www.cancernetwork.com/view/change-in-flush-practice-may-reduce-toxicity-for-adult-patients-with-cancer2026-05-14T19:00:00Z2026-05-14T19:00:00Z https://www.cancernetwork.com/view/the-evolving-roles-of-mrd-and-molecular-genotyping-in-non-hodgkin-lymphoma2026-05-14T18:00:00Z2026-05-14T18:00:00Z https://www.cancernetwork.com/view/breaking-silos-the-vital-role-of-oncology-training-programs-in-lymphoma2026-05-14T14:00:00Z2026-05-14T14:00:00Z https://www.cancernetwork.com/view/optimizing-therapeutic-strategies-across-the-nmibc-paradigm2026-05-14T12:00:00Z2026-05-14T12:00:00Z https://www.cancernetwork.com/view/115-evaluating-an-ai-based-prognostic-test-to-guide-adjuvant-cdk4-6-inhibitor-selection-in-early-hr-her2-breast-cancer2026-05-13T22:30:00Z2026-05-13T22:30:00Z https://www.cancernetwork.com/view/116-impact-of-neoadjuvant-chemotherapy-nact-response-on-clinical-outcomes-with-ribociclib-rib-in-hr-her2-ebc-a-subgroup-analysis-from-the-phase-3-natalee-trial2026-05-13T22:00:00Z2026-05-13T22:00:00Z https://www.cancernetwork.com/view/fda-oks-oral-decitabine-cedazuridine-plus-venetoclax-in-newly-diagnosed-aml2026-05-13T18:40:42.949Z2026-05-13T18:40:42.949Z https://www.cancernetwork.com/view/fda-approves-sonrotoclax-in-relapsed-refractory-mantle-cell-lymphoma2026-05-13T18:38:18.788Z2026-05-13T18:38:18.788Z https://www.cancernetwork.com/view/how-might-car-t-cells-and-bispecifics-evolve-in-multiple-myeloma-therapy-2026-05-13T18:00:00Z2026-05-13T18:00:00Z https://www.cancernetwork.com/view/novel-adenoid-cystic-carcinoma-drug-earns-fda-breakthrough-therapy-status2026-05-13T16:00:00Z2026-05-13T16:00:00Z https://www.cancernetwork.com/view/mitomycin-exhibits-sustained-36-month-responses-in-lg-ir-nmibc2026-05-13T15:30:00Z2026-05-13T15:30:00Z https://www.cancernetwork.com/view/the-unmet-needs-in-oncology-that-zedoresertib-lunresertib-targets2026-05-13T14:00:00Z2026-05-13T14:00:00Z https://www.cancernetwork.com/view/key-takeaways-for-early-relapse-multiple-myeloma-management2026-05-13T12:05:00Z2026-05-13T12:05:00Z https://www.cancernetwork.com/view/how-til-therapy-provides-durable-responses-in-refractory-melanoma2026-05-13T12:00:00Z2026-05-13T12:00:00Z https://www.cancernetwork.com/view/managing-comorbid-patients-in-early-relapse-multiple-myeloma2026-05-13T12:00:00Z2026-05-13T12:00:00Z https://www.cancernetwork.com/view/117-risk-of-recurrence-ror-among-patients-with-hr-her2-early-breast-cancer-ebc-involving-1-3-axillary-lymph-nodes-n1-a-real-world-evaluation2026-05-12T22:30:00Z2026-05-12T22:30:00Z https://www.cancernetwork.com/view/118-pooled-analysis-of-patients-treated-with-1st-line-1l-ribociclib-rib-endocrine-therapy-et-in-the-monaleesa-ml-studies-long-term-progression-free-survival-pfs-2026-05-12T22:00:00Z2026-05-12T22:00:00Z https://www.cancernetwork.com/view/how-is-zoldonrasib-different-from-other-therapies-in-kras-g12d-nsclc-2026-05-12T19:00:00Z2026-05-12T19:00:00Z https://www.cancernetwork.com/view/zoldonrasib-shows-promising-activity-in-kras-g12d-nsclc2026-05-12T18:00:00Z2026-05-12T18:00:00Z https://www.cancernetwork.com/view/mythic-trial-demonstrates-efficacy-in-platinum-resistant-ovarian-cancer2026-05-12T17:00:00Z2026-05-12T17:00:00Z https://www.cancernetwork.com/view/precision-medicine-with-duvelisib-and-the-evolving-landscape-of-lymphoma2026-05-12T14:00:00Z2026-05-12T14:00:00Z https://www.cancernetwork.com/view/selecting-among-preferred-1l-regimens-a-discussion2026-05-12T12:05:00.000Z2026-05-12T12:05:00Z https://www.cancernetwork.com/view/clinical-context-mariposa-efficacy-in-1l-egfrm-nsclc2026-05-12T12:00:00.000Z2026-05-12T12:00:00Z https://www.cancernetwork.com/view/119-progression-free-survival-pfs-and-overall-survival-os-results-from-the-phase-3-monaleesa-3-trial-of-postmenopausal-patients-with-hormone-receptor-positive-hr-human-epidermal-growth-factor-receptor-2-negative-her2-advanced-breast-cancer-abc-treated-with-ribociclib-rib-fulvestrant-ful-a-subgroup-analysis-of-patients-with-invasive-lobular-carcinoma-ilc-2026-05-11T22:30:00Z2026-05-11T22:30:00Z https://www.cancernetwork.com/view/what-is-the-future-of-til-therapy-in-metastatic-melanoma-2026-05-11T19:00:00Z2026-05-11T19:00:00Z https://www.cancernetwork.com/view/novel-hp1k-inhibitor-shows-favorable-responses-in-ccrcc-solid-tumors2026-05-11T17:00:00Z2026-05-11T17:00:00Z https://www.cancernetwork.com/view/fda-grants-rmat-designation-to-rz-001-in-advanced-hepatocellular-carcinoma2026-05-11T15:22:51.265Z2026-05-11T15:22:51.265Z https://www.cancernetwork.com/view/patient-reported-outcomes-and-quality-of-life-considerations2026-05-11T12:05:00Z2026-05-11T12:05:00Z https://www.cancernetwork.com/view/final-case-insights-and-future-directions-in-advanced-renal-cell-carcinoma2026-05-11T12:05:00Z2026-05-11T12:05:00Z https://www.cancernetwork.com/view/managing-fatigue-anemia-and-cardiovascular-risk-in-practice2026-05-11T12:00:00Z2026-05-11T12:00:00Z https://www.cancernetwork.com/view/what-does-the-future-hold-for-immune-effector-cell-therapies2026-05-11T12:00:00Z2026-05-11T12:00:00Z https://www.cancernetwork.com/view/managing-aggressive-disease-after-io-and-tki-in-advanced-renal-cell-carcinoma2026-05-11T12:00:00Z2026-05-11T12:00:00Z https://www.cancernetwork.com/view/121-five-year-analysis-of-distant-disease-free-survival-ddfs-across-key-subgroups-from-the-phase-3-natalee-trial-of-ribociclib-rib-plus-a-nonsteroidal-aromatase-inhibitor-nsai-in-patients-with-hr-her2-early-breast-cancer-ebc-2026-05-10T22:30:00Z2026-05-10T22:30:00Z https://www.cancernetwork.com/view/122-adjuvant-ribociclib-rib-plus-nonsteroidal-aromatase-inhibitor-nsai-in-patients-with-hr-her2-early-breast-cancer-ebc-natalee-5-year-outcomes2026-05-10T22:00:00Z2026-05-10T22:00:00Z https://www.cancernetwork.com/view/tazemetostat-and-belinostat-synergy-in-relapsed-refractory-lymphoma2026-05-10T18:00:00Z2026-05-10T18:00:00Z https://www.cancernetwork.com/view/123-real-world-patient-and-caregiver-experiences-with-breast-cancer-bc-risk-of-recurrence-ror-in-the-us-results-of-an-online-survey-and-social-media-analysis2026-05-09T22:30:00Z2026-05-09T22:30:00Z https://www.cancernetwork.com/view/124-real-world-progression-free-survival-2-and-tumor-response-of-cdk4-6is-aromatase-inhibitor-in-patients-with-hr-her2-metastatic-breast-cancer2026-05-09T22:00:00Z2026-05-09T22:00:00Z https://www.cancernetwork.com/view/tip125-rediscover-2-a-phase-3-study-of-zovegalisib-rly-2608-fulvestrant-versus-capivasertib-fulvestrant-as-treatment-for-locally-advanced-or-metastatic-pik3ca-mutant-hr-her2--breast-cancer-following-recurrence-or-progression-on-or-after-treatment-with-a-cdk4-6-inhibitor-trial-in-progress-2026-05-08T22:30:00Z2026-05-08T22:30:00Z https://www.cancernetwork.com/view/tip126-trofuse-011-a-phase-3-randomized-open-label-study-of-sacituzumab-tirumotecan-with-or-without-pembrolizumab-vs-treatment-of-physician-s-choice-for-previously-untreated-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer-with-pd-l1-combined-positive-score-102026-05-08T22:00:00Z2026-05-08T22:00:00Z https://www.cancernetwork.com/view/fda-approves-zenocutuzumab-in-nrg1-cholangiocarcinoma-post-systemic-therapy2026-05-08T19:19:41.305Z2026-05-08T19:19:41.305Z https://www.cancernetwork.com/view/daraxonrasib-shows-anti-tumor-activity-in-pretreated-ras-pancreatic-cancer2026-05-08T16:00:02.948Z2026-05-08T16:00:02.948Z https://www.cancernetwork.com/view/bridging-the-access-gap-for-bispecific-antibodies-in-community-oncology2026-05-08T12:00:00Z2026-05-08T12:00:00Z https://www.cancernetwork.com/view/tip127-trofuse-012-a-phase-3-randomized-study-of-adjuvant-sacituzumab-tirumotecan-plus-pembrolizumab-vs-treatment-of-physician-s-choice-in-participants-with-triple-negative-breast-cancer-who-received-neoadjuvant-therapy-and-did-not-achieve-a-pathological-complete-response-at-surgery2026-05-07T22:30:00Z2026-05-07T22:30:00Z https://www.cancernetwork.com/view/128-trofuse-032-a-phase-3-randomized-study-of-pembrolizumab-plus-sacituzumab-tirumotecan-or-chemotherapy-followed-by-pembrolizumab-plus-chemotherapy-for-early-stage-triple-negative-breast-cancer-or-hormone-receptor-low-positive-human-epidermal-growth-factor-receptor-2-negative-breast-cancer2026-05-07T22:00:00Z2026-05-07T22:00:00Z https://www.cancernetwork.com/view/epigenetic-priming-and-immunotherapy-synergy-across-the-lymphoma-space2026-05-07T18:00:00Z2026-05-07T18:00:00Z https://www.cancernetwork.com/view/the-intricacy-of-the-robotic-whipple-surgery-a-conversation-with-a-surgeon2026-05-07T17:00:00Z2026-05-07T17:00:00Z https://www.cancernetwork.com/view/fda-accepts-snda-for-taletrectinib-in-ros1-positive-nsclc2026-05-07T15:09:05.941Z2026-05-07T15:09:05.941Z https://www.cancernetwork.com/view/bridging-the-gap-overcoming-institutional-barriers-to-exercise-oncology2026-05-07T12:00:00Z2026-05-07T12:00:00Z https://www.cancernetwork.com/view/tip-129-the-role-of-vitamin-d-in-cdk4-6-inhibitor-therapy-for-breast-cancer2026-05-06T22:30:00Z2026-05-06T22:30:00Z https://www.cancernetwork.com/view/130-sacituzumab-govitecan-sg-pembrolizumab-pembro-vs-chemotherapy-chemo-pembro-in-previously-untreated-pd-l1-positive-advanced-triple-negative-breast-cancer-tnbc-primary-results-from-the-randomized-phase-3-ascent-04-keynote-d19-study2026-05-06T22:00:00Z2026-05-06T22:00:00Z https://www.cancernetwork.com/view/learning-to-implement-novel-cellular-therapies-in-hematologic-oncology-care2026-05-06T21:00:00Z2026-05-06T21:00:00Z https://www.cancernetwork.com/view/achieving-a-functional-cure-with-multiple-myeloma-therapy2026-05-06T20:00:00Z2026-05-06T20:00:00Z https://www.cancernetwork.com/view/zenocutuzumab-earns-fda-national-priority-voucher-in-cholangiocarcinoma2026-05-06T19:28:00.669Z2026-05-06T19:28:00.669Z